Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

被引：0
|
作者：
Norman, A. [1 ]
Wee, C. [1 ]
Hobday, T. [1 ]
Kendi, A. [1 ]
Johnson, G. [1 ]
Thorpe, M. [1 ]
Lunn, B. [1 ]
Bach, C. [1 ]
Eiring, R. [1 ]
Halfdanarson, T. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷
关键词：
midpoint imaging; prrt; clinical decision making;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K25
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [31] Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).
    Lung, Mei Sim
    Hofman, Michael
    Kong, Grace
    Thang, Sue-Ping
    Michael, Michael
    Hicks, Rodney J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: literature and practical aspects
    Di Dia, Amalia
    Ferrari, Mahila E.
    Travaini, Laura Lavinia
    Grappeja, Lorenza
    Guglielmo, Priscilla
    Barone, Antonio
    Mei, Riccardo
    Papi, Stefano
    Ceci, Francesco
    Grana, Chiara Maria
    CLINICAL AND TRANSLATIONAL IMAGING, 2025, : 121 - 129
  • [33] Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)
    Ladwa, R.
    Pattison, D.
    Smith, J.
    Goodman, S.
    Burge, M.
    Rose, S.
    Dowson, N.
    Wyld, D.
    NEUROENDOCRINOLOGY, 2018, 106 : 249 - 249
  • [34] Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)
    Duan, H.
    Song, H.
    Ferri, V
    Fisher, G.
    Shaheen, S.
    Shah, J.
    Nguyen, J.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Iagaru, A.
    Mari, Aparici C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 141 - 141
  • [35] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    PANCREAS, 2017, 46 (03) : 439 - 439
  • [36] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Kwekkeboom, Dik J.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Kam, Boen L.
    van Essen, Martijn
    Teunissen, Jaap J. M.
    Krenning, Eric P.
    SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
  • [37] Peptide receptor radionuclide therapy of neuroendocrine tumors
    Haug, A. R.
    Bartenstein, P.
    ONKOLOGE, 2011, 17 (07): : 602 - +
  • [38] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Bodei, Lisa
    Kidd, Mark
    Prasad, Vikas
    Modlin, Irvin M.
    NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, 2015, 44 : 198 - 215
  • [39] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Basu, Sandip
    Parghane, Rahul, V
    Kamaldeep
    Chakrabarty, Sudipta
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (05) : 447 - 464
  • [40] Peptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumor Patients with Carcinoid Heart Disease
    Prasad, V
    Secknus, M. A.
    Hoersch, D.
    Kuntze, T.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 133 - 133
12345